In addition to their CD1d-restricted T cell receptor (TCR), natural killer T (NKT) cells express various receptors normally associated with NK cells thought to act, in part, as modulators of TCR signaling. Immunoreceptor-tyrosine activation (ITAM) and inhibition (ITIM) motifs associated with NK receptors may augment or attenuate perceived TCR signals respectively, potentially influencing NKT cell development and function. ITIM-containing Ly49 family receptors expressed by NKT cells are proposed to play a role in their development and function. We have produced mice transgenic for the ITAM-associated Ly49D and ITIM-containing Ly49A receptors and their common ligand H2-Dd to determine the importance of these signaling interplays in NKT cell development. Ly49D/H2-Dd transgenic mice had selectively and severely reduced numbers of thymic and peripheral NKT cells, whereas both ligand and Ly49D transgenics had normal numbers of NKT cells. CD1d tetramer staining revealed a blockade of NKT cell development at an early precursor stage. Coexpression of a Ly49A transgene partially rescued NKT cell development in Ly49D/H2-Dd transgenics, presumably due to attenuation of ITAM signaling. Thus, Ly49D-induced ITAM signaling is incompatible with the early development of cells expressing semi-invariant CD1d-restricted TCRs and appropriately harmonized ITIM–ITAM signaling is likely to play an important role in the developmental program of NKT cells.
Skip Nav Destination
Article navigation
7 April 2003
Brief Definitive Report|
April 07 2003
Ligand-dependent Inhibition of CD1d-restricted NKT Cell Development in Mice Transgenic for the Activating Receptor Ly49D
Roger B. Voyle,
Roger B. Voyle
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Search for other works by this author on:
Friedrich Beermann,
Friedrich Beermann
2Swiss Institute for Experimental Cancer Research, 1066 Epalinges, Switzerland
Search for other works by this author on:
Rosemary K. Lees,
Rosemary K. Lees
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Search for other works by this author on:
Jens Schümann,
Jens Schümann
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Search for other works by this author on:
Jacques Zimmer,
Jacques Zimmer
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Search for other works by this author on:
Werner Held,
Werner Held
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Search for other works by this author on:
H. Robson MacDonald
H. Robson MacDonald
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Search for other works by this author on:
Roger B. Voyle
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Friedrich Beermann
2Swiss Institute for Experimental Cancer Research, 1066 Epalinges, Switzerland
Rosemary K. Lees
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Jens Schümann
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Jacques Zimmer
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Werner Held
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
H. Robson MacDonald
1Ludwig Institute For Cancer Research, Lausanne Branch, University of Lausanne
Address correspondence to H. Robson MacDonald, Ludwig Institute for Cancer Research, Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland. Phone: 41-21-692-59-89; Fax: 41-21-653-44-74; E-mail: [email protected]
Received:
September 12 2002
Revision Received:
February 03 2003
Accepted:
February 03 2003
Online ISSN: 1540-9538
Print ISSN: 0022-1007
The Rockefeller University Press
2003
J Exp Med (2003) 197 (7): 919–925.
Article history
Received:
September 12 2002
Revision Received:
February 03 2003
Accepted:
February 03 2003
Citation
Roger B. Voyle, Friedrich Beermann, Rosemary K. Lees, Jens Schümann, Jacques Zimmer, Werner Held, H. Robson MacDonald; Ligand-dependent Inhibition of CD1d-restricted NKT Cell Development in Mice Transgenic for the Activating Receptor Ly49D . J Exp Med 7 April 2003; 197 (7): 919–925. doi: https://doi.org/10.1084/jem.20021615
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement